First Trust Advisors LP trimmed its position in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) by 54.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 34,250 shares of the biotechnology company’s stock after selling 40,843 shares during the quarter. First Trust Advisors LP’s holdings in Momenta Pharmaceuticals were worth $579,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Texas Permanent School Fund boosted its holdings in Momenta Pharmaceuticals by 0.4% in the 1st quarter. Texas Permanent School Fund now owns 46,821 shares of the biotechnology company’s stock valued at $625,000 after purchasing an additional 201 shares during the last quarter. Municipal Employees Retirement System of Michigan boosted its holdings in Momenta Pharmaceuticals by 2.2% in the 1st quarter. Municipal Employees Retirement System of Michigan now owns 14,600 shares of the biotechnology company’s stock valued at $195,000 after purchasing an additional 310 shares during the last quarter. Envestnet Asset Management Inc. boosted its holdings in Momenta Pharmaceuticals by 3.0% in the 1st quarter. Envestnet Asset Management Inc. now owns 14,275 shares of the biotechnology company’s stock valued at $191,000 after purchasing an additional 411 shares during the last quarter. Arizona State Retirement System boosted its holdings in Momenta Pharmaceuticals by 2.4% in the 1st quarter. Arizona State Retirement System now owns 33,734 shares of the biotechnology company’s stock valued at $450,000 after purchasing an additional 800 shares during the last quarter. Finally, Louisiana State Employees Retirement System boosted its holdings in Momenta Pharmaceuticals by 3.4% in the 2nd quarter. Louisiana State Employees Retirement System now owns 27,200 shares of the biotechnology company’s stock valued at $460,000 after purchasing an additional 900 shares during the last quarter. Institutional investors own 93.86% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Momenta Pharmaceuticals, Inc. (MNTA) Holdings Trimmed by First Trust Advisors LP” was reported by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright legislation. The legal version of this piece of content can be read at https://www.dailypolitical.com/2017/09/25/momenta-pharmaceuticals-inc-mnta-holdings-trimmed-by-first-trust-advisors-lp.html.

In other Momenta Pharmaceuticals news, President Craig A. Wheeler sold 4,116 shares of Momenta Pharmaceuticals stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $15.07, for a total transaction of $62,028.12. Following the transaction, the president now directly owns 269,231 shares of the company’s stock, valued at $4,057,311.17. The sale was disclosed in a filing with the SEC, which is available at this link. Also, President Craig A. Wheeler sold 20,367 shares of Momenta Pharmaceuticals stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $17.00, for a total transaction of $346,239.00. The disclosure for this sale can be found here. Insiders sold 43,996 shares of company stock worth $735,755 over the last three months. Corporate insiders own 4.40% of the company’s stock.

Several equities analysts have weighed in on MNTA shares. BidaskClub upgraded shares of Momenta Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, June 23rd. Stifel Nicolaus reiterated a “buy” rating and issued a $26.00 target price on shares of Momenta Pharmaceuticals in a report on Thursday, August 3rd. Zacks Investment Research downgraded shares of Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. Finally, Maxim Group set a $6.00 price target on shares of Momenta Pharmaceuticals and gave the company a “sell” rating in a research note on Thursday, August 3rd. Three equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the company’s stock. Momenta Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $16.63.

Shares of Momenta Pharmaceuticals, Inc. (NASDAQ MNTA) opened at 17.15 on Monday. Momenta Pharmaceuticals, Inc. has a 1-year low of $10.75 and a 1-year high of $19.90. The stock has a 50 day moving average of $16.43 and a 200-day moving average of $15.55. The stock’s market capitalization is $1.27 billion.

Momenta Pharmaceuticals (NASDAQ:MNTA) last released its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.50). Momenta Pharmaceuticals had a negative net margin of 39.35% and a negative return on equity of 12.28%. The business had revenue of $23.57 million for the quarter, compared to analysts’ expectations of $24.64 million. During the same period last year, the company earned ($0.31) earnings per share. The company’s quarterly revenue was down 10.8% on a year-over-year basis. Equities research analysts predict that Momenta Pharmaceuticals, Inc. will post ($1.39) earnings per share for the current fiscal year.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Institutional Ownership by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.